shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
25 August 2022Big PharmaSarah Speight

GSK presses court to deny Teva’s ‘skinny label’ petition

Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 October 2022   Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Big Pharma
4 October 2022   Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Big Pharma
4 October 2022   Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.